By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – BG Medicine today announced a collaboration with Boston Scientific to study whether galectin-3 can be used to screen patients for cardiac-resynchronization therapy.

Data for their effort will come from the MADIT-CRT study, the world's largest randomized study of New York Heart Association Class I and II patients. The study involves more than 1,800 patients enrolled in 110 centers worldwide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.